- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Procter & Gamble Health Limited reported sales of ₹304 crores for the quarter ended December 31, 2024, remaining flat compared to the previous year. Profit After Tax (PAT) increased significantly, reaching ₹91 crores, a 26% rise year-over-year. Excluding a one-time item from the prior year, operational PAT grew by 13%. The Managing Director highlighted the company's focus on reinforcing its supply network and maintaining an integrated growth strategy, which includes a focused product portfolio and a commitment to consumer needs. An interim dividend of ₹80 per equity share has been declared, with a record date set for February 21, 2025. A positive outlook suggests that the company’s strategic initiatives may lead to sustained growth.